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Abstract
Background: Colorectal cancer (CRC) multiplicity has been mainly related to polyposis and non-polyposis hereditary
syndromes. In sporadic CRC, aberrant gene promoter methylation has been shown to play a key role in carcinogenesis,
although little is known about its involvement in multiplicity. To assess the effect of methylation in tumor multiplicity in
sporadic CRC, hypermethylation of key tumor suppressor genes was evaluated in patients with both multiple and solitary
tumors, as a proof-of-concept of an underlying epigenetic defect.
Methodology/Principal Findings: We examined a total of 47 synchronous/metachronous primary CRC from 41 patients,
and 41 gender, age (5-year intervals) and tumor location-paired patients with solitary tumors. Exclusion criteria were
polyposis syndromes, Lynch syndrome and inflammatory bowel disease. DNA methylation at the promoter region of the
MGMT, CDKN2A,S FRP1, TMEFF2, HS3ST2 (3OST2), RASSF1A and GATA4 genes was evaluated by quantitative methylation
specific PCR in both tumor and corresponding normal appearing colorectal mucosa samples. Overall, patients with multiple
lesions exhibited a higher degree of methylation in tumor samples than those with solitary tumors regarding all evaluated
genes. After adjusting for age and gender, binomial logistic regression analysis identified methylation of MGMT2 (OR, 1.48;
95% CI, 1.10 to 1.97; p=0.008) and RASSF1A (OR, 2.04; 95% CI, 1.01 to 4.13; p=0.047) as variables independently associated
with tumor multiplicity, being the risk related to methylation of any of these two genes 4.57 (95% CI, 1.53 to 13.61;
p=0.006). Moreover, in six patients in whom both tumors were available, we found a correlation in the methylation levels of
MGMT2 (r=0.64, p=0.17), SFRP1 (r=0.83, 0.06), HPP1 (r=0.64, p=0.17), 3OST2 (r=0.83, p=0.06) and GATA4 (r=0.6,
p=0.24). Methylation in normal appearing colorectal mucosa from patients with multiple and solitary CRC showed no
relevant difference in any evaluated gene.
Conclusions: These results provide a proof-of-concept that gene promoter methylation is associated with tumor
multiplicity. This underlying epigenetic defect may have noteworthy implications in the prevention of patients with
sporadic CRC.
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Colorectal cancer (CRC) is a relevant public health problem
since it represents the second most common malignant tumor and
also the second leading cause of cancer death in Western
countries. Inheritance constitutes the underlying cause in up to
one third of all CRC cases, with highly penetrant and well-defined
hereditary disorders, i.e. adenomatous and hamartomatous
polyposis and Lynch syndrome, representing 3–5% of the total
CRC burden [1]. In such conditions, presence of a germline
mutation in the causative gene (i.e. APC, MYH, LKB1, SMAD4,
BMPR1A, PTEN, MLH1, MSH2, MSH6 and PMS2) [1,2],
predisposes these individuals to the development of multiple
colorectal neoplasms. Indeed, whereas familial adenomatous
polyposis represents the paradigm of tumor multiplicity, presence
of either synchronous or metachronous CRC is also one of the
most common clinical criteria for suspecting Lynch syndrome [3].
Besides the above-mentioned inherited conditions, tumor
multiplicity is also a frequent observation in patients with CRC
who are not apparently predisposed to these neoplasms on the
basis of their genetic background. In fact, synchronous and
metachronous colorectal adenomas are reported in up to 30% and
48% of patients with sporadic CRC, respectively, while the
corresponding figures for carcinoma are 4% and 9%, respectively
[4,5]. In this setting, evident familial cancer aggregation or
distinctive personal characteristics are not openly distinguished,
and although a generalized cellular or molecular disorder in the
entire colorectal mucosa may be suspected, the underlying
pathogenic mechanism remains elusive.
A field effect underlying colorectal carcinogenesis is a
well recognized situation in patients with inflammatory
bowel disease, a premalignant condition with an increased
cumulative risk for developing CRC associated with early
age of onset, disease duration, and extent and severity of
inflammation [6,7]. The precise mechanism by which chronic
colonic mucosal inflammation causes malignancy in this context
is poorly understood, although it is supposed to be related
to a failure in regulatory mechanisms during cell division.
Chronic inflammation leads to the release of free radicals from
leucocytes and macrophages, and these reactive oxygen species
can drive carcinogenesis by causing DNA damage [8]. Since
in most cases DNA damage leads to inactivation of tumor
suppressor genes, the concept of ‘‘field effect’’ could be better
designated as ‘‘field defect’’. Putative involvement of such a field
defect in sporadic CRC, however, has not been satisfactorily
established so far.
Sporadic CRC arises as a consequence of the accumulation of
genetic and epigenetic alterations that transform colonic epithelial
cells into colon adenocarcinoma cells [9]. The loss of genomic
stability and resulting gene alterations are key molecular
pathogenic steps that occur early in tumorigenesis: they permit
the acquisition of a sufficient number of alterations in tumor
suppressor genes and oncogenes that transform cells and promote
tumor progression. Analogous to genomic instability, epigenetic
instability results in the aberrant methylation of tumor suppressor
genes [9]. In fact, epigenetic tumor suppressor gene silencing has
commonly been involved in all types of human tumors, including
CRC [10]. Aberrant cytosine methylation plays a preeminent role
in cell transformation when it affects genes that safeguard genome
instability. This epigenetic change can also be detected in
precancerous lesions and seemingly normal peritumor tissues
[11,12,13,14,15], thus suggesting its potential involvement in the
initial carcinogenetic process. This putative field defect associated
with gene promoter hypermethylation in normal appearing
colorectal mucosa has been suggested with respect to the MGMT
gene [12], as well as ERa, MYOD, P16(INK4A), MLH1, TIMP3
and DAPK [13].
Considering that hypermethylation of promoter regions in
tumor suppressor genes could be observed in normal appearing
colorectal mucosa, we hypothesized that this phenomenon would
be especially relevant in patients who developed multiple CRC.
Therefore, the aim of this study was to evaluate methylation
patterns of genes involved in colorectal carcinogenesis through this
mechanism in both tumor tissue and normal appearing colorectal
mucosa samples of patients with multiple and solitary CRC, as a
proof-of-concept of a putative underlying epigenetic defect
associated with tumor multiplicity.
Materials and Methods
Patients
We examined a total of 47 synchronous/metachronous primary
CRC from 41 patients (36 synchronous, 4 metachronous and one
both) and 41 gender, age (5-year intervals) and tumor location-
paired patients with solitary tumors. Control patients with solitary
tumors were recruited in the EPICOLON project, a prospective,
multicenter, nation-wide, population-based cohort (n=1,222) [16]
and randomly selected among those with no previous CRC and
with a minimum follow-up of 5 year after the diagnosis of cancer
in which regular colonoscopy surveillance did not identify any
additional lesion. Regarding patients with multiple CRC, 31 were
also recruited in the EPICOLON project and 10 additional
patients at the Endoscopy Unit of the Hospital Clı ´nic of Barcelona
between June 2007 and May 2008. There were no differences with
respect to the clinicopathological characteristics of both sets of
patients with multiple lesions (data not shown). Exclusion criteria
for the present study were colorectal polyposis syndromes, Lynch
syndrome and personal history of inflammatory bowel disease.
Demographic, clinical and tumor-related characteristics of patients
included in the study are summarized in Table 1. The study was
approved by the institutional Ethics Committee of each partici-
pating hospital, and written informed consent was obtained from
all patients. Members of the EPICOLON project are listed in Note
S1.
Frozen tumor and corresponding normal-appearing, peritumor
colorectal mucosa tissues were obtained either at surgery or
endoscopy from all patients, and immediately stored at 280uC
until use. In patients with multiple lesions, tissue sample was
obtained from at least one tumor (the most advanced one or the
largest when multiple tumors had the same tumor stage).
DNA Isolation and Bisulfite Treatment
Frozen samples were thawed and genomic DNA was isolated
using the QIAamp DNA Mini KitH (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. Bisulfite treat-
ment was carried out on genomic DNA using the EZ DNA
Methylation-Gold KitH (Zymo Research, Orange, CA) according
to the manufacturer’s protocol with minor modifications detailed
below [17]. This procedure integrated the DNA denaturation and
bisulfite conversion into one-step, using temperature denaturation
to replace chemical denaturation with sodium hydroxide, and it
was based on a three-step reaction process between cytosine and
sodium bisulfite that converts unmethylated cytosines into uracils.
An amount of 250 ng of genomic DNA isolated from each tumor
or normal tissue sample was used per reaction, and a volume
of 15 ml was employed for each bisulfited DNA to be eluted.
The resulted DNA was used for PCR amplification or stored at
280uC.
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After bisulfite conversion, duplicates of 0.5 ml of each bisulfited
DNA were amplified by the MethyLight technique, a previously
described fluorescence-based quantitative real-time PCR, highly
specific, sensitive and reproducible assay [18]. Locus specific PCR
primers and probes for seven tumor suppressor genes –MGMT1
(minimal promoter), MGMT2 (enhancer region), CDKN2A,
SFRP1, TMEFF2, HS3ST2 (3OST2), RASSF1A and GATA4– were
specifically designed for bisulfited-converted DNA sequences and
located at each gene promoter region. These genes were chosen
for their involvement in colorectal carcinogenesis through
methylation-driven silencing and evidence of some degree of
hypermethylation in normal-appearing, peritumor colorectal
mucosa counterpart (Table 2). In that sense, it is important to
emphasize that genes proposed as markers of the CpG island
methylator phenotype which, by definition, are almost exclusively
methylated in cancer tissue were avoided. Primer and probes used
for bisulfited DNA sequences are listed on Table S1. Fully
unmethylated and fully Sssl-methylated DNA were employed
initially as 0 and 100% methylated references to test amplification
results, and methylated DNA was further used as calibrator for all
tested samples. ALUC4 gene was used as endogenous reference to
normalize for the amount of input DNA [19]. The MethyLight
reactions were performed on a 7300 Real Time PCR System
(Applied Biosystems, Foster City, CA) with a final volume of
12.5 ml containing 900 nM of each primer and 250 nM of the
corresponding probe. The PCR conditions were: 95uC for
10 minutes, followed by 40 cycles at 92uC for 15 seconds and
58uC for 1 minute, as it was previously described [18].
Each measurement in a given sample was performed in
duplicate for both tested and endogenous genes, and the threshold
cycle (Ct) –the fractional number at which the amount of amplified
target reached a fixed threshold– was determined. The standard
deviation in sample duplicates was always below 0.2. Relative
amounts of both genes were also normalized to commercial 100%
methylated DNA (Zymo Research, Orange, CA) acting as
calibrator to allow comparison across all tested samples. The
comparative Ct method [20], also known as the 2
2DDCt method,
was calculated from
DDCt~DCt sample{DCt calibrator
where
DCt, sample was the tested genes Ct value for any sample
normalized to ALUC4, and
DCt, calibrator was the tested genes Ct
value for the calibrator also normalized to ALUC4. The result
derived from the
DDCt 6100 corresponds to percentage of
methylated reference (PMR), which indicates the percentage of
fully methylated molecules at a specific locus [21].
Investigators performing the methylation specific PCR real-time
experiments were blinded to the clinical characteristics of patients
(i.e. tumor multiplicity).
Evaluation of Tumor Mismatch Repair Deficiency
Tumor mismatch repair deficiency was evaluated by both
immunostaining and microsatellite instability testing. Immunohis-
tochemical analysis included evaluation of MSH2 (anti-MSH2,
Oncogene Research Products, Boston, MA), MLH1 (anti-MLH1,
PharMingen, San Diego, CA) and MSH6 (anti-MSH6, BD
Table 1. Characteristics of patients included in the study.
Multiple CRC
(n=41)
Solitary CRC
(n=41)
P
value
1
Age (yrs.)
2 74.368.2 74.969.1 0.97
Gender –no. (%) 0.82
male 28 (68.3%) 26 (63.4%)
female 13 (31.7%) 15 (36.6%)
Tumor location –no. (%)
3 1.0
right 25 (61.0%) 25 (61.0%)
left 16 (39.0%) 16 (39.0%)
Tumor stage –no. (%)
3 0.82
I 4 (9.8%) 5 (12.1%)
II 15 (36.6%) 19 (46.3%)
III 13 (31.7%) 12 (29.3%)
IV 7 (17.1%) 5 (12.2%)
Tumor multiplicity –no. (%) -
synchronous 36 (87.8%) NA
metachronous 4 (9.8%) NA
both 1 (2.4%) NA
Synchronous adenoma –no. (%) 25 (61.0%) 1 (2.4%) 0.001
Personal history of other
neoplasms –no. (%)
4
1 (2.4%) 1 (2.4%) 1.0
Family history of colorectal
cancer –no. (%)
5
5 (12.2%) 7 (17.1%) 0.76
Family history of other
neoplasms –no. (%)
5
2 (4.9%)
6 5 (12.2%) 0.43
endometrial 2 1
gastric 1 3
ovary - 1
Tumor DNA mismatch repair
deficiency –no. (%)
3 (7.3%) 2 (4.9%) 0.64
CRC, colorectal cancer; NA, not applied.
1Qualitative variables were compared by the Fisher’s exact test; continuous
variables were compared by the Mann-Whitney U’s test.
2Results expressed as mean 6 standard deviation.
3In patients with multiple tumors, characteristics were referred to the most
advanced lesion.
4Other neoplasms included small bowel and ovary, respectively.
5Family history was referred to first degree relatives.
6One patient had both endometrial and gastric cancer.
doi:10.1371/journal.pone.0008777.t001
Table 2. Genes evaluated in the study.
Gene
abbreviation Gene name
GenBank
accession no. Reference
MGMT O6-methylguanine-DNA-
methyltransferase
NM_002412 [12,14,41,42,43]
CDKN2A
(p16)
Cyclin-dependent
kinase inhibitor 2 A
NM_000077 [13,44,45]
SFRP1 Secreted frizzled-
related protein 1
NM_003012 [46,47]
TMEFF2 Transmembrane protein
with EGF-like and two
follistatin-like domains 2
NM_016192 [48,49]
HS3ST2
(3OST2)
Heparan sulfate
(glucosamine) 3-O-
sulfotransferase 2
NM_006043 [36,50]
RASSF1A Ras association (RalGDS/AF-
6) domain family member 1
AF132675 [33,34,35,36,37]
GATA4 GATA binding protein 4 NM_002052 [51]
doi:10.1371/journal.pone.0008777.t002
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[16]. Tumor cells were judged to be negative for protein
expression only if they lacked staining in a sample in which
normal colonocytes and stroma cells were stained. If no
immunostaining of normal tissue could be demonstrated, the
results were considered unreliable. Microsatellite instability was
assessed using the 5-marker panel proposed by the National
Cancer Institute and/or the pentaplex of mononucleotide repeats,
as described elsewhere [22].
Statistical Analysis
Comparison of methylation degree between multiple and
solitary CRC patients was performed qualitatively where
methylation positivity was set as PMR $4, as previously
validated [23]. Since information regarding methylation in
normal appearing colorectal mucosa was limited, the analysis
in this setting was performed according to both a $4P M Rc u t -
off and an additional, arbitrarily chosen $1P M Rc u t - o f fi no r d e r
to ascertain any potential minor effect. The analysis was
performed using the Fisher’s exact test. Correlation between
methylation levels of tumor pairs was analyzed by Spearman
correlation analysis.
Comparison between patients with multiple and solitary
tumors regarding the m e t h y l a t i o nd e g r e ei nb o t ht u m o ra n d
normal appearing colorectal mucosa samples was also performed
using binomial logistic regression, both unadjusted and adjusted
for age and gender. Furthermore, we tested the independent
effect of gene methylation on tumor multiplicity by including all
evaluated genes in the binomial logistic regression model, along
with age and gender. These variables were ‘‘pruned’’ using an
automated stepwise procedure for optimizing the Akaike
information criterion [24]. Multiplicative interactions were
tested for each pair of genes independently associated with
tumor multiplicity by including both main effects and an
interaction term (a product of two main effects) in the logistic
regression model. Finally, we tested the cumulative effects of
methylated genes on tumor multiplicity by counting the number
of selected genes independently associated with this phenomenon
in each subject. The odds ratio for tumor multiplicity for patients
carrying any combination of the selected methylated genes was
estimated by comparing them with patients carrying none of
these genes with the use of logistic regression analysis. Statistical
analyses were carried out using ‘‘R’’ (R Core Development team,
http://www.R-project.org).
Continuous variables were expressed as mean 6 standard
deviation. All p values were two sided. A p value of less than 0.05
was considered to indicate a statistically significant difference.
Results
Forty-one patients with either synchronous or metachronous
CRC, and 41 gender, age and tumor location-paired patients with
solitary tumors constituted the basis of this study. As it is shown in
Table 1, both groups of patients were similar with respect to any
demographic, clinical and tumor-related characteristics, except for
the presence of synchronous colorectal adenomas.
Gene Promoter Methylation in Tumor Samples
Comparison of gene promoter methylation in tumor samples
from patients with multiple and solitary CRC is depicted in
Table 3. Overall, patients with multiple lesions exhibited a higher
degree of methylation in tumor samples than those with solitary
tumors regarding all evaluated genes. The proportion of tumors
exhibiting gene promoter hypermethylation was significantly
higher in patients with multiple lesions than in those with solitary
CRC with respect to MGMT2 (40.4% vs. 14.6%, respectively;
p=0.009) and RASSF1A (17.0% vs. 0%, respectively; p=0.006)
(Table 3).
Estimation of the risk of tumor multiplicity associated with gene
promoter methylation in tumor samples is shown in Table 4. After
adjusting for age and gender, binomial logistic regression analysis
indicated that methylation of promoter regions of the MGMT1
locus (odds ratio (OR), 1.57; 95% confidence interval (CI), 1.01 to
2.43; p=0.04), MGMT2 locus (OR, 1.50; 95% CI, 1.14 to 1.96;
p=0.003), and RASSF1A gene (OR, 2.02; 95% CI, 1.03 to 3.93;
p=0.03) were associated with an increased risk of developing
multiple CRC (Table 4).
The adjusted multivariate logistic regression analysis identified
methylation of the MGMT2 locus (OR, 1.48; 95% CI, 1.10 to
1.97; p=0.008) and RASSF1A gene (OR, 2.04; 95% CI, 1.01 to
4.13; p=0.047) as variables independently associated with tumor
multiplicity. In addition, when the product of these two variables
was added to the regression model, this interaction term was not
selected (OR, 0.88; 95% CI, 0.67 to 1.16; p=0.37). Lastly, when
the cumulative effects of methylated genes was evaluated, the risk
of tumor multiplicity associated with methylation of any of these
two selected genes was 4.57 (95% CI, 1.53 to 13.61; p=0.006),
with no significant increase when both genes were simultaneous-
ly methylated (OR, 2.31; 95% CI, 0.00 to undetermined;
p=0.99).
Table 3. Gene promoter methylation in tumor samples.
Multiple CRC
(n=47)
Solitary CRC
(n=41) P value
1
MGMT1-Mp 0.21
methylated -no. (%) 8 (17.0) 3 (7.3)
unmethylated-no. (%) 39 (83.0) 38 (92.7)
MGMT2-Enh 0.009
methylated -no. (%) 19 (40.4) 6 (14.6)
unmethylated-no. (%) 28 (49.6) 35 (85.4)
CDKN2A 0.08
methylated -no. (%) 10 (21.3) 3 (7.3)
unmethylated-no. (%) 37 (78.7) 38 (92.7)
SFRP1 0.53
methylated -no. (%) 42 (89.4) 34 (82.9)
unmethylated-no. (%) 5 (10.6) 7 (17.1)
TMEFF2 0.66
methylated -no. (%) 20 (42.6) 15 (36.6)
unmethylated-no. (%) 27 (57.4) 36 (63.4)
HS3ST2 (3OST2) 0.46
methylated -no. (%) 37 (78.7) 29 (70.7)
unmethylated-no. (%) 10 (21.3) 12 (29.3)
RASSF1A 0.006
methylated -no. (%) 8 (17.0) - (-)
unmethylated-no. (%) 39 (83.0) - (-)
GATA4 0.057
methylated -no. (%) 38 (80.9) 25 (60.9)
unmethylated-no. (%) 9 (19.1) 16 (39.1)
CRC, colorectal cancer.
1Variables were compared by the Fisher’s exact test.
doi:10.1371/journal.pone.0008777.t003
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subset of six patients with multiple tumors in whom both tumors
were available for analysis (Figure 1). This analysis showed a non-
significant correlation in the methylation levels of MGMT2 (r=64,
p=0.17), SFRP1 (r=0.83, 0.06), HPP1 (r=0.64, p=0.17), 3OST2
(r=0.83, p=0.06), and GATA4 (r=0.6, p=0.24). MGMT1 and
CDKN2A did not show evidence of concordance between tumors
in the same patient (r=20.05, p=0.91; r=20.09, p=0.91,
respectively), and RASSF1A was rarely methylated in these tumors,
which precluded a proper correlation analysis.
Gene Promoter Methylation in Normal Appearing
Colorectal Mucosa Samples
Methylation in normal appearing colorectal mucosa from
patients with multiple and solitary CRC showed no relevant
difference in any evaluated gene (Table 5). In order to ascertain
any potential minor effect, the analysis was repeated using a $1
PMR cut-off (Table 5). In this second analysis, no consistent
methylation pattern was observed, with some genes showing
hypermethylation (i.e. MGMT1, MGMT2 and RASSF1A) and
others hypomethylation (i.e. SFRP1, TMEFF2 and GATA4)i n
patients with multiple lesions. None of these differences were
statistically significant (Table 5).
Discussion
Results of this study demonstrate that tumors from patients with
synchronous and metachronous CRC exhibit a higher degree of
methylation than those from patients with solitary lesions. Tumor
hypermethylation of the MGMT gene enhancer region and the
RASSF1A gene promoter region were identified as variables
independently associated with a five-fold increased risk of
developing multiple lesions. Moreover, we found similar methyl-
ation patterns in tumor pairs from the same patient. Overall, these
observations provide a proof-of-concept of an epigenetic defect
mediated by gene promoter hypermethylation which favor tumor
multiplicity in sporadic CRC.
Strengths of this study rely on the fact that it was carried out on
a general population through a prospective, multicenter, nation-
wide study in which unselected and consecutive patients with CRC
were included regardless of their personal and familial character-
istics; previous genetic characterization performed in the context
of the EPICOLON project allowed an adequate identification and
subsequent exclusion of patients with inherited disorders (i.e.
colorectal polyposis, Lynch syndrome and MYH-associated CRC)
[16,22,25,26,27,28], in whom a specific and well-defined molec-
ular mechanism justifies tumor multiplicity; it represents the
largest series of patients with multiple lesions evaluated so far for
tumor methylation, as well as the first study in which a control
group of patients with a solitary lesion was included with adequate
stratification for gender, age and tumor location; and finally,
quantitative methylation specific PCR was performed in both
tumor sample and paired normal appearing colorectal mucosa,
and data analyzed in a blinded fashion.
We are aware, however, of some limitations of this study. First,
RNA samples were not available to perform parallel expression
analyses and verify the biological significance of gene promoter
methylation. Nevertheless, there is a large body of evidence that
MethyLight assays provide an excellent correlation between
promoter methylation and gene silencing in similar tumor settings
[11,29]. More uncertainty exists, however, with respect to the
value of these results in non-neoplastic tissues. Although it has
been suggested that the epigenetic signature of cancers may have
early-stage, normal-tissue counterparts potentially involved in the
initiation of carcinogenetic process [14], it is still unclear if the
same cut-off of methylation used for tumor samples (i.e. PMR $4)
can be employed in non-neoplastic tissues. In order to overcome
this limitation, results obtained in normal appearing colorectal
mucosa were analyzed using two different cut-off levels. Second,
this study represents a candidate-gene, hypothesis-driven investi-
gation in which a reduced number of genes were chosen on the
basis of previous information demonstrating their involvement in
colorectal carcinogenesis through methylation-mediated gene
silencing, and evidence of a decreasing degree of hypermethylation
among tumor, peritumor normal appearing colorectal mucosa,
and normal colorectal mucosa from non-tumor individuals. The
main purpose of this approach was to provide a proof-of-concept
of the potential involvement of gene promoter hypermethylation
in tumor multiplicity rather than identifying the epigenetic
signature underlying this process. To reach this latter goal, high-
throughput techniques with genome wide capability are required,
an approach currently ongoing in our laboratory. Third,
evaluation of normal-appearing colorectal mucosa was limited to
the peritumor area in the vast majority of cases, since most samples
were obtained from surgical specimens. This aspect precludes
generalizing the results obtained in seemingly normal mucosa to
the entire colon. Indeed, striking colon segment-specific differences
in the prevalence of methylation of some genes (i.e. MLH1 and
Table 4. Risk of tumor multiplicity based on gene promoter
methylation in tumor
1.
Unadjusted Adjusted
2
OR 95% CI P value OR 95% CI P value
MGMT1-Mp
unmethylated 1 (ref) - 1 (ref) -
methylated 1.58 1.02–2.44 0.03 1.57 1.01–2.43 0.04
MGMT2-Enh
unmethylated 1 (ref) - 1 (ref) -
methylated 1.48 1.14–1.93 0.003 1.50 1.14–1.96 0.003
CDKN2A
unmethylated 1 (ref) - 1 (ref) -
methylated 1.23 0.92–1.65 0.15 1.23 0.92–1.65 0.16
SFRP1
unmethylated 1 (ref) - 1 (ref) -
methylated 1.06 0.87–1.29 0.51 1.06 0.87–1.29 0.55
TMEFF2
unmethylated 1 (ref) - 1 (ref) -
methylated 1.13 0.89–1.43 0.29 1.13 0.89–1.44 0.29
HS3ST2 (3OST2)
unmethylated 1 (ref) - 1 (ref) -
methylated 1.12 0.90–1.38 0.29 1.12 0.90–1.40 0.29
RASSF1A
unmethylated 1 (ref) - 1 (ref) -
methylated 1.95 1.01–3.74 0.04 2.02 1.03–3.93 0.03
GATA4
unmethylated 1 (ref) - 1 (ref) -
methylated 1.10 0.89–1.35 0.34 1.10 0.89–1.36 0.34
OR, odds ratio; 95% CI, 95% confidence interval.
1Binomial logistic regression analysis.
2Adjusted by age and gender.
doi:10.1371/journal.pone.0008777.t004
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affect the potential use of methylation analysis in CRC risk
assessment and, consequently, putative methylation-driven screen-
ing and surveillance strategies, is currently being evaluated.
A field defect mediated by MGMT gene promoter methylation
has been previously suggested [12]. In that seminal study,
hypermethylation of the MGMT gene was observed in 46% of
tumors as well as in 50% of normal appearing colorectal mucosa
samples of patients in whom MGMT promoter methylation was
foundinthecorrespondingtumor.Inanotherstudy,participationof
DNA methylation in five CIMP-specific gene promoters, including
MGMT,wasalsoevaluatedinsixsynchronouscarcinomapairs[30].
In this study, it was observed that while some tumor pairs showed
discordant methylation patterns, others showed similar, but not
exactly identical, profiles of promoter methylation, suggesting that
epigenetic alterations in synchronous CRClikely haveboth random
and nonrandom components [30]. Recently, Konishi et al. found
significant differences in methylation between multiple tumors
compared to solitary lesions for MGMT (26.5% vs. 17.3%; p,0.05)
and p14 (16.1% vs. 9.3%; p,0.05) [31]. Interestingly, these authors
found a significant correlation for methylation of different genes,
includingMGMT,betweentumorpairsofthe samesite(proximalvs.
distal). Unfortunately, this interesting issue could only be partially
addressed in our investigation since, because of the design of the
EPICOLON project, only one tumor sample was collected from
most patients with synchronous CRC, thus limiting this pair-wise
comparison to 6 patients. Although the positive correlations for
MGMT2 did not reach statistical significance (probably due the low
number of paired tumors available), our results are consistent with
the data obtained by Konishi et al. [31], supporting the hypothesis
that patients with multiple tumors show concordant methylation in
their tumor tissues. Very recently, in a seminal publication, LINE-1
Figure 1. Correlation in methylation levels of MGMT2, SFRP1, 3OST2, HPP1 and GATA4 in 6 tumor pairs from patients with multiple
tumors in whom both lesions were available. Results are expressed as percentage of methylation based on PMR.
doi:10.1371/journal.pone.0008777.g001
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CRC pairs, thus reinforcing the hypothesis of a field effect [32].
Methylation-associated inactivation of RASSF1A has been
frequently observed in several human malignancies including
sporadic CRC [33,34,35,36,37]. Indeed, tumor promoter hyper-
methylation of RASSF1A occurs in approximately 20% of CRC,
and it seems to exist a mutually exclusive relationship with the
presence of KRAS mutations [34,35]. Interestingly, in tumors with
mismatch repair deficiency, no significant differences were
observed in the frequency of RASSF1A methylation between
unstable sporadic CRC and tumors associated with Lynch
syndrome [37]. The above mentioned results [32], along with
the demonstration of RASSF1A methylation in tumor samples from
patients with multiple lesions, and the lack of differences in other
factors predisposing to tumor multiplicity (i.e. family history) favor
the hypothesis of an underlying epigenetic defect. However,
whether this methylation-driven gene silencing mechanism
represents a potential field effect due to an unidentified molecular
alteration in normal mucosa or the expression of pre-existing
multiple hyperplastic polyps from which CRC arises through the
serrated pathway [38], as it has been recently suggested [32],
remains unknown.
As it was mentioned, aberrant methylation of some CpG islands
has been seen in normal appearing colorectal mucosa. In one
study [13], this phenomenon was demonstrated for the ERa and
MYOD genes, as well as for the P16(INK4A), MLH1, TIMP3 and
DAPK genes at a lower level. Interestingly, some gene polymor-
phisms were associated with a lower methylation of the CpG
islands examined, thus suggesting that genetic factors can influence
this epigenetic alteration in normal colorectal mucosa [13]. The
physiological conditions associated with aberrant promoter
methylation in seemingly normal colorectal mucosa have also
been recently evaluated with respect to two DNA-repair genes,
MLH1 and MGMT [14]. In that study, samples from males
showed no consistent patterns for either promoter, but the
prevalence of MLH1 and MGMT methylation increased signifi-
cantly with age, particularly in the right colon, and were consistent
with current epigenetic profiles of CRC subsets. Similar results
were obtained in a third study, in which methylation frequencies of
colorectal adenomas were intermediate between CRC and
seemingly normal mucosa [36]. Regarding the role of methylation
in normal appearing colonic mucosa, Konishi et al. recently
evaluated the methylation status of several genes (MINT1, MINT2,
MINT31, MLH1, p14, p16, MGMT, and ESR1) in the tumor-
adjacent normal mucosa from patients with multiple and solitary
tumors, and found no significant differences between both groups
[31]. The methylation levels for all genes, except for MGMT and
ESR1, were at a vey low level. It is important to note that the low
level of methylation in normal appearing colorectal mucosa
observed in our study, in a similar manner as in others [13,31],
may be due to the circumscription of this phenomenon to limited
areas (aberrant crypt foci, for instance) rather than a spread,
diffuse alteration throughout the colon [39]. Another possibility
would be that this molecular event may affect some specific
cellular subtypes, the recent identified colon cancer tumor-
initiating cells being the most attractive candidate [40].
In conclusion, results of this study demonstrate that sporadic
CRC multiplicity is associated with gene promoter methylation. If
further investigations were able to identify the epigenetic signature
associated with tumor multiplicity and/or provide further
evidence of a potential field defect, a new approach to CRC risk
assessment and prevention would be available.
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